Non-Thermal Irreversible Electroporation And Immune System Enabled Tissue Engineering
- Technology Benefits
- Process can carry out the cell removal in the absence of any chemicals, toxins or enzymes typically used to in order to eliminate the cells.No need for immunosuppressant drugsReduced risk of graph rejectionECM rich in cell signaling components essential for cell adhesion, migration, proliferation and differentiationECM has a greater resistance to infection as compared to synthetic materials
- Technology Application
- Methods of treatment (e.g, tissue repair or regeneration)Non-thermal irreversible electroporation
- Detailed Technology Description
- None
- Supplementary Information
- Patent Number: US20120226218A1
Application Number: US13391577A
Inventor: Phillips, Mary | Maor, Elad | Rubinsky, Boris | Lavee, Jacob
Priority Date: 4 Sep 2009
Priority Number: US20120226218A1
Application Date: 27 Apr 2012
Publication Date: 6 Sep 2012
IPC Current: A61M003700 | A61K003512 | A61K003522 | A61K003534 | A61K003538 | A61K003542
US Class: 604020 | 424520 | 424551 | 424557 | 424558 | 424569
Title: EXTRACELLULAR MATRIX MATERIAL CREATED USING NON-THERMAL IRREVERSIBLE ELECTROPORATION
Usefulness: EXTRACELLULAR MATRIX MATERIAL CREATED USING NON-THERMAL IRREVERSIBLE ELECTROPORATION
Summary: The extracellular matrix is useful: for a treatment in a mammal (human); in cosmetic surgery; for repair of a body part; and for treating damaged tissue, which is used in cosmetic surgery and to kill cells in a target area of tissue, the tissue of an organ is a blood vessel, a heart, a lung, an intestine, and a bladder. The NTIRE is useful to kill cells on a segment of a human blood vessel for use in transplantation to repair another vessel in the same human and live cells are endothelial cells (all claimed). Test details are described but no results given.
Novelty: Extracellular matrix produced by subjecting target area of tissue to non-thermal irreversible electroporation, allowing mammal's immune system to remove killed cells and extracting target area, used e.g. to treat damaged tissue
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- 8835166
- Others
-
Publication
Irreversible Electroporation on the Small Intestine
User Defined 2
Nonthermal Irreversible Electroporation for Tissue Decellularization
Additional Technologies by these Inventors
Tech ID/UC Case
21043/2010-016-0
Related Cases
2010-016-0
- *Abstract
-
Treatment of disease and trauma to the coronary arteries and the peripheral vessels often includes the use of bypass grafting. Autologous grafts are most often used and are typically taken from the saphenous vein, internal mammary artery, or the radial artery; however, this method is not an option in patients without a vein that is suitable to use. Also, the costs for harvesting autologous vessels are considerable, and there is a significant level of morbidity associated with the procedure. Also, the use of synthetic grafts in small diameter vessels tends to lead to poor compliance and low patency, often resulting in thrombogenicity. Furthermore, although recent tissue engineering methods have focused on a variety of tissue decellularization methods, these methods risk damage to the extracellular membrane (ECM), which acts as a scaffold for tissue repair and regeneration, compromising the scaffold's further development and integration into the recipient's body.
UC Scientists have developed an alternative technology that does not have the disadvantages and shortcomings seen in both autologous and synthetic grafts. Such technology includes a method of treatment comprising subjecting a target area of tissue in a mammal to non-thermal irreversible electroporation (NTIRE) in order to kill cells at the target site without the use of any chemical agents, toxins, enzymes or use of physical devices beyond the NTIRE devices. After the immune system has removed cells killed with the NTIRE, and before there is substantial growth of new cells the tissue is removed from the mammal and transplanted to a repair site, all of which is carried out in the absence of any immunosuppressant drugs.
- *Applications
-
- *IP Issue Date
- Sep 16, 2014
- *Principal Investigator
-
Name: Elad Maor
Department:
Name: Mary Phillips
Department:
Name: Boris Rubinsky
Department:
Name: Jacob Lavee
Department:
- Country/Region
- USA
